Why the study?
Does intravenous dextran therapy reduce the incidence of postoperative pulmonary emboli in postoperative patients?
Does intravenous dextran therapy reduce the incidence of postoperative pulmonary emboli in postoperative patients?
Intravenous dextran therapy is effective in decreasing the incidence of postoperative pulmonary emboli, particularly fatal ones, by about fivefold.
Answers are grounded in this paper and cite their sources.
Should not change practice on Level 5 autopsy data; leaves open need for contemporary RCTs on dextran in surgical patients.
Dextran is a plasma volume expander which has antithrombotic effects. Some of these effects may be nonspecific and due to hemodilution and venous flow improvement. However, dextran also has specific antithrombotic effects that cause a temporary change in the structure and function of Factor VIII (antihemophilic globulin), which results in a decrease in platelet aggregability and thrombus stability. Intravenous dextran therapy has no marked effect on the incidence of small, early postoperative thrombi as detected by 125 Iodine‐fibrinogen, but it produces a significant decrease in the incidence of thrombi that can be diagnosed phlebographically or clinically. The most marked effect of dextran is on pulmonary emboli, and particularly on fatal pulmonary emboli as seen at autopsy, where it produces about a fivefold decrease in incidence. It is concluded that the antithrombotic properties of dextran are particularly useful in decreasing the incidence of postoperative pulmonary emboli .
No takes yet. Share an insight, caveat, or question.
Sven ‐Erik Bergentz (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: